Colloidal formulations of etoposide based on poly(butyl cyanoacrylate) nanoparticles: Preparation, physicochemical properties and cytotoxicity

Yordanov, Georgi; Skrobanska, Ralica; Evangelatov, Alexander

doi:10.1016/j.colsurfb.2012.05.040

Cited by 35 publications

(16 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At fixed time intervals up to 24 h (1440 min), 3 mL aliquots were withdrawn of the external medium for quantification of the photosensitizer by the fluorescence method. After the measurement, each aliquot was put back to the receiver vessel in order to maintain a constant volume (Yordanov et al, 2010(Yordanov et al, , 2013.As a comparison, the release kinetic of the free photosensitizer was also investigated using the same external medium mentioned above. The fluorescence intensity of the samples was utilized to calculate the concentrations of ZnPc released and to plot the release profile (time versus drug release (%)).…”

Section: In Vitro Release Kinetic Analysismentioning

confidence: 99%

Evaluation of photodynamic activity, photostability and in vitro drug release of zinc phthalocyanine-loaded nanocapsules

Souza

Ziembowicz

Müller

et al. 2016

European Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Section: In Vitro Release Kinetic Analysismentioning

confidence: 99%

Evaluation of photodynamic activity, photostability and in vitro drug release of zinc phthalocyanine-loaded nanocapsules

Souza

Ziembowicz

Müller

et al. 2016

European Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

“…Etoposide (ETP), a semi-synthetic derivative of podophyllotoxin, is the inhibitor of deoxyribonucleic acid topoisomerase II that has a significant activity against malignant lymphoma, small cell lung cancer, stomach cancer and ovarian cancer (Yordanov et al, 2013). However, because of its low solubility, the short biological half-life (1.5 h), poor bioavailability and severe side effects, it is urgent to overcome these drawbacks and improve the clinical therapy effect .…”

Section: Introductionmentioning

confidence: 99%

Targeted delivery of etoposide to cancer cells by folate-modified nanostructured lipid drug delivery system

Zhang

Zhang³

et al. 2016

Drug Delivery

View full text Add to dashboard Cite

Context: Cardiotoxicity and myelosuppression of etoposide (ETP) limited its clinical application. Targeted drug delivery system could deliver anticancer agents to the target cancerous cells, thus reducing their toxicity. Objective: In this study, folate (FA) was applied for the construction of nanostructured lipid carriers (NLCs), and used for targeted delivery of ETP to tumors overexpresses the FA receptors. Methods: FA-poly (ethylene glycol)-distearoylphosphatidylethanolamine was synthesized. FA decorated and ETP-loaded NLCs (FA-ETP-NLCs) were prepared and the formulation was optimized by Box-Behnken design. Their particle size (PS), zeta potential and drug encapsulation efficiency (EE) was evaluated. In vitro cytotoxicity studies of FA-ETP-NLCs were tested in CT26, SGC7901, NCI-H209 cell lines. In vivo antitumor efficacies of the carriers were evaluated on mice bearing CT26 cells xenografts. Results: The optimum FA-ETP-NLCs formulations had a PS of 120.86 nm. The growth of CT26, SGC790 or NCI-H209 cells in vitro was obviously inhibited. FA-ETP-NLCs also displayed the best antitumor activity than other formulations in vivo. Conclusion: The results demonstrated that FA-ETP-NLCs were efficient in selective delivery to CT26, SGC790 or NCI-H209 cells overexpressing the FA receptors. Also, FA-ETP-NLCs can sufficiently transfer ETP to the cancer cells, enhance the antitumor capacity. Thus, FA-ETP-NLCs could prove to be a superior nanomedicine to achieve tumor therapeutic efficacy.

show abstract

“…This necessitates repetitive high dosages and severe side effects. Moreover, deficiencies such as metabolic inactivation, drug resistance, myelosuppression, poor bioavailability and secondary acute myelocytic leukemia, which occur in a several percentage of patients have limited their scopes of applications (Qin et al, 2013;Yordanov et al, 2013). On the other hand, curcumin (CUR) is a natural remedy, and has been shown to enhance the antitumor efficacy of ETP for prostate cancer (Shukla et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

Co-delivery of etoposide and curcumin by lipid nanoparticulate drug delivery system for the treatment of gastric tumors

Jiang

Geng²,

Liu³

et al. 2016

Drug Delivery

View full text Add to dashboard Cite

Context: Gastric carcinoma (GC) is one of the most common cancers and the second most frequent cause of cancer-related deaths. Chemotherapy is an important therapeutic modality for GC. However, chemoresistance limited its success rate. Combination chemotherapy is often applied to prevent drug-induced resistance in cancers.Objective: The aim of this study is to evaluate whether the co-delivery of etoposide (ETP) and curcumin (CUR) with one nanoparticle can result in synergistic effects of both drugs. Methods: ETP-and CUR-loaded nanostructured lipid carriers (ETP-CUR-NLC) were prepared by the solvent injection technique. Their average size, zeta potential and drug loading were evaluated. Human gastric cancer cell lines (SGC7901 cells) were used for the testing of in vitro cytotoxicity studies, and in vivo anti-tumor efficacies of the carriers were evaluated on mice bearing SGC7901 cells xenografts.Results: ETP-CUR-NLC has a particle size of 114 nm, EPT-loading quantity of 83% and CURloading quantity of 82%. ETP-CUR-NLC displayed high cytotoxicity and enhanced antitumor activity in vitro and in vivo. Meanwhile, ETP-CUR-NLC displayed low cytotoxicity in normal tissues in vivo. Discussion and conclusion: The results demonstrate that ETP-CUR-NLC can achieve impressive anti-tumor activity. By combining CUR, an effective NF-kB inhibitor, with ETP, a powerful anticancer drug, in NLC, we could improve the therapeutic efficacy in cancer treatments. Our results showed that such co-loaded delivery systems could serve as a promising therapeutic approach to improve clinical outcomes against various malignancies.

show abstract

Colloidal formulations of etoposide based on poly(butyl cyanoacrylate) nanoparticles: Preparation, physicochemical properties and cytotoxicity

Cited by 35 publications

References 58 publications

Evaluation of photodynamic activity, photostability and in vitro drug release of zinc phthalocyanine-loaded nanocapsules

Evaluation of photodynamic activity, photostability and in vitro drug release of zinc phthalocyanine-loaded nanocapsules

Targeted delivery of etoposide to cancer cells by folate-modified nanostructured lipid drug delivery system

Co-delivery of etoposide and curcumin by lipid nanoparticulate drug delivery system for the treatment of gastric tumors

Contact Info

Product

Resources

About